期刊文献+

Recent applications and strategies in nanotechnology for lung diseases 被引量:6

原文传递
导出
摘要 Lung diseases,including COVID-19 and lung cancers,is a huge threat to human health.However,for the treatment and diagnosis of various lung diseases,such as pneumonia,asthma,cancer,and pulmonary tuberculosis,are becoming increasingly challenging.Currently,several types of treatments and/or diagnostic methods are used to treat lung diseases;however,the occurrence of adverse reactions to chemotherapy,drug-resistant bacteria,side effects that can be significantly toxic,and poor drug delivery necessitates the development of more promising treatments.Nanotechnology,as an emerging technology,has been extensively studied in medicine.Several studies have shown that nano-delivery systems can significantly enhance the targeting of drug delivery.When compared to traditional delivery methods,several nanoparticle delivery strategies are used to improve the detection methods and drug treatment efficacy.Transporting nanoparticles to the lungs,loading appropriate therapeutic drugs,and the incorporation of intelligent functions to overcome various lung barriers have broad prospects as they can aid in locating target tissues and can enhance the therapeutic effect while minimizing systemic side effects.In addition,as a new and highly contagious respiratory infection disease,COVID-19 is spreading worldwide.However,there is no specific drug for COVID-19.Clinical trials are being conducted in several countries to develop antiviral drugs or vaccines.In recent years,nanotechnology has provided a feasible platform for improving the diagnosis and treatment of diseases,nanotechnology-based strategies may have broad prospects in the diagnosis and treatment of COVID-19.This article reviews the latest developments in nanotechnology drug delivery strategies in the lungs in recent years and studies the clinical application value of nanomedicine in the drug delivery strategy pertaining to the lung.
出处 《Nano Research》 SCIE EI CSCD 2021年第7期2067-2089,共23页 纳米研究(英文版)
基金 This research was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China(No.2018ZX10301402) the National Natural Science Foundation of China(No.51973243) the International Cooperation and Exchange of the National Natural Science Foundation of China(No.51820105004) the Guangdong Innovative and Entrepreneurial Research Team Program(No.2016ZT06S029) the Guangdong Basic and Applied Basic Research Foundation(No.2019A1515110903) the Sanming Project of Medicine in Shenzhen(No.SZSM201911004) the Research Start-up Fund of Post-doctoral,of SAHSYSU(No.ZSQYRSFPD0016).
  • 相关文献

参考文献3

二级参考文献45

  • 1Zheng-hongWU Qi-nengPING YiWEI Jia-mingLAI.Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice[J].Acta Pharmacologica Sinica,2004,25(7):966-972. 被引量:8
  • 2Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
  • 3Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
  • 4Wiemik, P. H. Anthracyclines: Current status and new development. Academic Press, NY 1980.
  • 5Chatterjee, K.; Zhang, J. Q.; Honbo, N.; Karliner, J. S. Doxorubicin cardiomyopathy. Cardiol. 2010, 115, 155-162.
  • 6Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe,C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 7Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of atp-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
  • 8Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch,1.L. et al. Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323, 1718-1722.
  • 9Bums, J. S.; Abdallah, B. M.; Guldberg, P.; Rygaard, J.; Schroder, H. D.; Kassem, M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res. 2005, 65, 3126-3135.
  • 10Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.

共引文献25

同被引文献19

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部